News stories about ImmuCell Corporation (NASDAQ:ICCC) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmuCell Corporation earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.3002894508831 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

ImmuCell Corporation (NASDAQ ICCC) traded up 7.47% on Wednesday, hitting $6.19. 11,926 shares of the stock traded hands. ImmuCell Corporation has a 52 week low of $4.76 and a 52 week high of $8.24. The stock has a market cap of $31.25 million, a price-to-earnings ratio of 71.15 and a beta of 1.07. The firm’s 50 day moving average is $6.52 and its 200 day moving average is $6.12.

ImmuCell Corporation (NASDAQ:ICCC) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.05) EPS for the quarter. The firm had revenue of $1.75 million during the quarter. ImmuCell Corporation had a net margin of 4.55% and a return on equity of 2.25%.

Separately, TheStreet upgraded shares of ImmuCell Corporation from a “c” rating to a “b-” rating in a report on Monday, June 12th.

TRADEMARK VIOLATION NOTICE: “ImmuCell Corporation (ICCC) Earns Daily Media Impact Rating of 0.07” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at

In other news, insider Brian L. Pessin purchased 30,000 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of $5.25 per share, for a total transaction of $157,500.00. Following the completion of the purchase, the insider now directly owns 70,000 shares in the company, valued at approximately $367,500. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 20.10% of the company’s stock.

ImmuCell Corporation Company Profile

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell Corporation (NASDAQ:ICCC)

Receive News & Stock Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related stocks with our FREE daily email newsletter.